A pilot study has further confirmed that CD19 CAR-T cells with concurrent ibrutinib for R/R CLL were well tolerated, with low CRS severity, and contribute to high rates (61%) of MRD-negative response (116). The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.